HC Wainwright & Co. Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $245

Benzinga · 3d ago
HC Wainwright & Co. analyst Robert Burns initiates coverage on Inhibrx Biosciences (NASDAQ:INBX) with a Buy rating and announces Price Target of $245.